RecruitingPhase 1NCT06894979
Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma
Studying Astrocytoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Oncology Group
- Principal Investigator
- Erin K BarrPediatric Early Phase Clinical Trial Network
- Intervention
- ATM Kinase Inhibitor AZD1390(drug)
- Enrollment
- 54 enrolled
- Eligibility
- 22 years · All sexes
- Timeline
- 2025 – 2028
Study locations (17)
- Children's Hospital of Alabama, Birmingham, Alabama, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Children's Hospital of Orange County, Orange, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
- Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
- Riley Hospital for Children, Indianapolis, Indiana, United States
- C S Mott Children's Hospital, Ann Arbor, Michigan, United States
- University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
- Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States
- +2 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06894979 on ClinicalTrials.govOther trials for Astrocytoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07552467Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant TumorsUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGEARLY PHASE1NCT07284069Senicapoc and Perampanel for Newly Diagnosed GlioblastomaAarhus University Hospital
- RECRUITINGPHASE2NCT05653635Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II StudyCentre Paul Strauss
- RECRUITINGPHASE1NCT07343986Study of Low-Intensity Focused Ultrasound in Combination With Immunotherapy in Newly Diagnosed Unmethylated GlioblastomaUniversity of Virginia
- RECRUITINGPHASE2NCT07417761Tuvusertib in Astrocytoma With ATRX MutationGrupo Español de Investigación en Neurooncología
- RECRUITINGNANCT06466031Application of FET-PET in Fusion With MRI in the Treatment of Glioblastoma Multiforme [TYR-GLIO]Copernicus Memorial Hospital
- RECRUITINGNANCT06930846HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)Dartmouth-Hitchcock Medical Center
- RECRUITINGPHASE3NCT07100730Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent GlioblastomaTelix Pharmaceuticals (Innovations) Pty Limited